HD-OPM Archive
Topics › PCSK9, ezetimibe & newer drugs

Ezetimibe beyond statins: fewer events, no mortality gain in trials, registry benefits

Gokhan Can · Nov 07, 2024 · ♥ 11 reactions · 22 comments · original Facebook post
PCSK9, ezetimibe & newer drugsLDL, ApoB & lipid panelStatins
AI summary & key facts

Evidence digest on ezetimibe. A meta-analysis of 15 RCTs (123,785 patients) found add-on lipid lowering cut cardiovascular events 19% versus statins alone but did not improve all-cause mortality. Other data show moderate statin plus ezetimibe matches high-intensity statins, and registry studies hint at lower mortality, with strong LDL-target attainment.

Ezetimibe Lipid-Lowering Therapy Beyond Statins

(TL;DR It just works. Multiple benefits throughout studies. Image from Canadian primary prevention study.)

1. Mortality and Cardiovascular Outcomes:

2. Combination Therapy vs High-Intensity Statin Monotherapy:

3. Real-World Effectiveness (Finnish Registry Study):

4. Primary Prevention Outcomes:

5. Secondary Prevention and Target Achievement:

6. Special Populations - Elevated Lipoprotein(a):

7. Triple Therapy Results:

8. Meta-analysis of Combination LLT vs Statin Monotherapy:

9. Systematic Review of Secondary Prevention:

Key Conclusions:

1. Efficacy:

2. Safety:

3. Clinical Implementation:

4. Specific Populations:

These findings suggest that combination lipid-lowering therapy, particularly moderate-intensity statin plus ezetimibe, offers an effective and well-tolerated alternative to high-intensity statin monotherapy. The evidence supports its use in both primary and secondary prevention, with particular benefits in high-risk populations. However, real-world implementation remains suboptimal, suggesting a need for improved clinical adoption strategies and patient education to maximize therapeutic benefits.

References:

Research cited

#ezetimibe#statins#mortality#prevention#cardiovascular#rosuvastatin#stroke#bempedoicacid
← newer: Adding ezetimibe to a statin lowers CRP by an extra 10% in polder: Fish oil dosing: aiming for 3 g EPA and 1 g DHA per day →